fda bans compounded semaglutide and tirzepatide Moves to Close a GLP-1 Loophole: What the 503B Proposal Means for Patients What Patients Need to Know

in 2017 and by the EU in 2018, Ozempic is developed and sold by Danish pharma juggernaut Novo Nordisk, and was originally meant for patients with Type 2 diabetes

The stomach is a muscular organ capable of significant expansion and contraction, and there is no established link between GLP-1 receptor agonist therapy and anatomical changes that would constitute true stomach shrinkage

These combined factors create a perfect storm for weight regain unless deliberately countered with structured lifestyle interventions

Still, this work may set the stage for the first-ever medication to aid in cocaine dependency treatment